Demethylzeylasteral exerts potent efficacy against non-small-cell lung cancer via the P53 signaling pathway

doi:10.1016/j.tranon.2024.101989

科研成果详情

题名	Demethylzeylasteral exerts potent efficacy against non-small-cell lung cancer via the P53 signaling pathway
作者	Lv, Linxi 1,2,3; Zhou, Feng 1,2,3; Quan, Yizhou 4; Fan, Yiwei 2; Bao, Yunjia 1; Dou, Yaning2; Qu, Hongyan2; Dai, Xuanxuan1,5; Zhao, Haiyang 3; Zheng, Suqing2; Zhao, Chengguang1,2; Yang, Lehe 1,3
发表日期	2024-08-01
发表期刊	Translational Oncology; 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Activator Demethylzeylasteral Non-small-cell lung cancer P53
其他关键词	WILFORDII HOOK F ; MUTANT P53 ; PROLIFERATION ; ACTIVATION ; APOPTOSIS ; ARTHRITIS ; INVASION ; TARGET
摘要	Lung cancer has one of the highest mortality rates worldwide, with non-small-cell lung cancer (NSCLC) constituting approximately 85% of all cases. Demethylzeylasteral (DEM), extracted from Tripterygium wilfordii Hook F, exhibits notable anti-tumor properties. In this study, we revealed that DEM could effectively induce NSCLC cell apoptosis. Specifically, DEM can dose-dependently suppress the viability and migration of human NSCLC cells. RNA-seq analysis revealed that DEM regulates the P53-signaling pathway, which was further validated by assessing crucial proteins involved in this pathway. Biacore analysis indicated that DEM has high affinity with the P53 protein. The CDX model demonstrated DEM's anti-tumor actions. This work provided evidence that DEM-P53 interaction stabilizes P53 protein and triggers downstream anti-tumor activities. These findings indicate that DEM treatment holds promise as a potential therapeutic approach for NSCLC, which warrants further clinical assessment in patients with NSCLC.
资助项目	Wenzhou Municipal Science and Technology Bureau[H20210009,ZY2020025];Zhejiang Medical Health Science and technology Program[2019RC204];National Natural Science Funding of China[82203322,82173856];Quzhou Science & Technology Bureau[2023K110];Natural Science Foundation of Zhejiang Province[LY21H300005,Y24H160151];
出版者	Neoplasia Press, Inc.
ISSN	1936-5233
卷号	46
DOI	10.1016/j.tranon.2024.101989
页数	13
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:001245204500001
收录类别	SCOPUS ; PUBMED ; SCIE
URL	查看原文
PubMed ID	38781861
SCOPUSEID	2-s2.0-85193541178
通讯作者地址	[Yang, Lehe]The First Affiliated Hospital,Wenzhou Medical University,Building 3, Nanbaixiang Street,Wenzhou,325000,China ; [Zheng, Suqing]School of Pharmaceutical Sciences,Wenzhou Medical University,Building 11, Chashan Street, University Town,Wenzhou,325035,China
Scopus学科分类	Oncology;Cancer Research
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/213370
专题	附属第一医院药学院（分析测试中心）其他_温州医科大学附属衢州医院
通讯作者	Zheng, Suqing; Zhao, Chengguang; Yang, Lehe
作者单位	1.The First Affiliated Hospital,Wenzhou Medical University,Zhejiang,Wenzhou,325000,China; 2.School of Pharmaceutical Sciences,Wenzhou Medical University,Zhejiang,Wenzhou,325035,China; 3.The Institute of Life Sciences,Wenzhou University,Zhejiang,Wenzhou,325035,China; 4.School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing,100029,China; 5.The Quzhou Affiliated Hospital of Wenzhou Medical University,Quzhou People's Hospital,Quzhou,324000,China
第一作者单位	附属第一医院; 药学院（分析测试中心）
通讯作者单位	附属第一医院; 药学院（分析测试中心）
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Lv, Linxi,Zhou, Feng,Quan, Yizhou,et al. Demethylzeylasteral exerts potent efficacy against non-small-cell lung cancer via the P53 signaling pathway[J]. Translational Oncology;,2024,46.
APA	Lv, Linxi., Zhou, Feng., Quan, Yizhou., Fan, Yiwei., Bao, Yunjia., ... & Yang, Lehe. (2024). Demethylzeylasteral exerts potent efficacy against non-small-cell lung cancer via the P53 signaling pathway. Translational Oncology;, 46.
MLA	Lv, Linxi,et al."Demethylzeylasteral exerts potent efficacy against non-small-cell lung cancer via the P53 signaling pathway".Translational Oncology; 46(2024).